Patient-Reported Outcomes for Determining Prognostic Groups in Veterans With Advanced Cancer

Abstract Context Physicians overestimate survival in patients with advanced cancer. Patient-reported outcomes could provide another way to estimate survival. We previously reported four prognostic groups based on Karnofsky Performance Status, Functional Assessment of Cancer Therapy physical well-bei...

Full description

Saved in:
Bibliographic Details
Published in:Journal of pain and symptom management 2015-09, Vol.50 (3), p.313-320
Main Authors: Chang, Victor T., MD, Scott, Charles B., PhD, Gonzalez, Melanie L., MPH, Einhorn, Jan, RN, Yan, Houling, BS, Kasimis, Basil S., MD, DSc
Format: Article
Language:English
Subjects:
Aged
Anesthesia & Perioperative Care
Female
Functional Assessment of Cancer Therapy
Humans
Kaplan-Meier Estimate
Karnofsky Performance Status
Male
Memorial Symptom Assessment Scale-Short Form
Neoplasms - diagnosis
Pain Medicine
Patient Outcome Assessment
Prognosis
Proportional Hazards Models
Prospective Studies
Quality of Life
recursive partitioning algorithm
Self Report
survival
symptoms
Veterans - psychology
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Abstract Context Physicians overestimate survival in patients with advanced cancer. Patient-reported outcomes could provide another way to estimate survival. We previously reported four prognostic groups based on Karnofsky Performance Status, Functional Assessment of Cancer Therapy physical well-being subscale, and Memorial Symptom Assessment Scale-Short Form physical symptom distress subscale scores. Objectives To determine the validity of these four prognostic groups. Methods We performed prospective surveys. Data from a total of 880 Veterans Affairs Medical Center patients, 417 in the First Cohort and 463 in the Validation Cohort, were analyzed. Both inpatients and outpatients were prospectively recruited in Institutional Review Board-approved studies from August 1999 to September 2009. Survival was measured from the date of entry until death or December 1, 2009. Patients completed self-assessments with the Functional Assessment of Cancer Therapy and Memorial Symptom Assessment Scale-Short Form. Analysis of variance was used to test differences between groups in continuous variables; a generalized Wilcoxon test was used for differences between groups for survival. Results The average age in the Validation Cohort was 66.5 years and 98% were men. The majority of patients had metastatic cancer (90%), with lung (28%) and prostate (26%) cancers being predominant. The median Karnofsky Performance Status was 70. Median survival was 33, 46.5, 124, and 209.5 days for the four prognostic groups ( P  
ISSN:0885-3924
1873-6513
DOI:10.1016/j.jpainsymman.2015.03.016